S'abonner

Évolution épidémiologique de la leptospirose en Guyane (EVOLEPTO), 2016-2022 - 13/12/24

Doi : 10.1016/j.mmifmc.2024.11.005 
M. Zenou 1, , P. Bourhy 2, M. Demar 3, P. Abboud 3, F. Djossou 3, A. Kpangon 4, H. Kallel 3, J.-F. Carod 5, P. Selles 6, S. Trombert Paolantoni 6, A. Barbry 7, M. Picardeau 2, L. Epelboin 3, P. Le Turnier 3
1 CHU Toulouse 
2 CNR leptospirose 
3 CH Cayenne 
4 CH Kourou 
5 CH Ouest Guyanais 
6 Laboratoire Cerba France 
7 Laboratoire Eurofins Biomnis France 

Corresponding author.

Résumé

Objective

Leptospirosis is a worldwide zoonotic disease, caused by Leptospira spp, whose incidence has been constantly increasing over the past decades. French Guiana (FG) is a French overseas department located in South America, covered mainly by Amazonian forest. The last update of leptospirosis epidemiology in FG dates back to 2014. The aim of this retrospective study was to provide an actualization of human leptospirosis epidemiology in FG.

Material and methods

We conducted a multicentric, cross-sectional study in the three main hospitals of French Guiana (Cayenne and Kourou). Cases of leptospirosis from 2016 to 2022 were retrospectively identified via a systematic screening of all positive serology and polymerase chain reaction (PCR) results. Cases were classified as confirmed, probable based on serology titers and PCR results. Cases with differential diagnosis for cases with positive IgM only were excluded. Infecting serogroups were determined by microscopic agglutination test (MAT) or sequencing of the PCR products. Medical files were reviewed to extract epidemiological data in standardized form. Preliminary results of 2 hospitals (Cayenne and Kourou) are presented here.

Results

On the study period 177 cases were identified, 129 (73%) confirmed and 48 (27%) probable. The incidence increased from 2.4/100,000 in 2016 to 10.4/100,000 in 2022, way higher than the incidence reported by the French National Reference Center on leptospirosis in 2014 which was 0.6/100,000. Median age was 38 (IQR 29-53) years, the male/female ratio was 3.1. The most frequent country of birth was Haïti (n=48/159, 30.2%). Thirty three cases (33/87, 37.9%) declared living in informal settlements. Diagnosis was suspected upon admission for 56,1% of the patients. All subjects reported at least one exposure: mainly rodent proximity (n=69/104, 66.4%) followed by fresh water exposure (n=68/77, 88.3%). One hundred and forty (79.1%) patients were hospitalized, among them 28 (20%) in intensive care unit. Among the whole population 26 cases (14,7%) were classified as severe: 14 (7.91%) underwent extra renal epuration, 8 (4.52%) oro-tracheal intubation, 21 (11.86%) received amines and 4 (2,26%) died. The predominant serogroups were Icterohaemorragiae (n=28/55, 50.9%), Canicola (n=8/55, 14.5%). Leptospirosis cases managed during exceptional rainy years of 2021 and 2022 tended to affect more precarious populations based on housing type and health insurance (not significant). Compared to the 2007-2014 period, patients were older, with a smaller male/female ratio and had more comorbidities, severe forms and lethality rate were similar, initial diagnosis was more frequent and biological diagnosis was mainly made by blood PCR, urine PCR being scarcely prescribed.

Discussion

Although leptospirosis incidence has increased drastically in the last ten years, clinical and outcome patients’ characteristics, especially severe forms rate, remained stable. However this study revealed changes in the sociodemographic characteristics suggesting that leptospirosis may particularly affect migrant populations from informal settlements or living in precarious conditions. Other studies conducted in these locations and populations as well as in animal and environmental reservoirs would be interesting to complete this data.

Le texte complet de cet article est disponible en PDF.

© 2024  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 3 - N° 4S

P. S2-S3 - décembre 2024 Retour au numéro
Article précédent Article précédent
  • Comparaison des données cliniques et histologiques des cas de lèpre en Guyane de 2011 à 2024: impact de l'histologie sur la décision thérapeutique
  • Q. Boscals de Reals, J. Lebret, K. Drak Alsibai, R. Blaizot, G. Grotta
| Article suivant Article suivant
  • Surveillance de pathogènes zoonotiques dans les eaux usées en Guyane sur la période 2020-2021
  • M. Combe, P. Le Turnier, L. Epelboin, J.-F. Carod, R.E. Gozlan

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.